Completed PHASE2 INTERVENTIONAL 2-arm NCT00192517

Study of MEDI-522 Administered by Subcutaneous Injection to Adults With Plaque Psoriasis

A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of MEDI-522, a Humanized Monoclonal Antibody to Integrin Alpha V Beta 3, Administered by Subcutaneous Injection to Adults With Plaque Psoriasis

Sponsor: MedImmune LLC

Conditions Psoriasis

Interventions MEDI-522 Placebo

Updated 7 times since 2017 Last updated: Apr 2, 2009 Started: Dec 31, 2003 Primary completion: Aug 31, 2004 Completion: Sep 30, 2004

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Psoriasis, this trial is completed. The trial is conducted by MedImmune LLC and has accumulated 7 data snapshots since 2003. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

7 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE2
Sep 2024 — Sep 2025 [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2

▶ Show 2 earlier versions

Feb 2017 — Jun 2018 [monthly]

Completed PHASE2
Jan 2017 — Feb 2017 [monthly]

Completed PHASE2

First recorded

Dec 2003

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

MedImmune LLC

Data source: MedImmune LLC

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Allentown, United States , Alpharetta, United States , Cincinnati, United States , Clinton Township, United States , Fresno, United States , Jacksonville, United States , Johnson City, United States , Johnston, United States , Little Rock, United States , Nashville, United States and 10 more locations